docwirenews.com
Guselkumab Shows Efficacy for Perianal Fistulizing Crohn's Disease - Docwire News
Perianal fistulas are a significant complication of Crohn’s disease that can be hard to treat. A phase 3 trial reported that guselkumab improved combined fistula remission versus placebo, which could represent a new treatment option if confirmed and approved.
Adults with perianal fistulizing Crohn’s disease, clinicians who treat IBD, and researchers interested in biologic therapies targeting IL‑23.
What To Know
Guselkumab (an IL‑23p19 antagonist) showed higher combined fistula remission rates than placebo at Week 24 in the phase 3 FUZION trial for patients with perianal fistulizing Crohn’s disease.
The trial enrolled patients with at least one draining perianal fistula and prior inadequate response to conventional therapies; guselkumab was given after IV induction and then as subcutaneous maintenance at two dosing regimens. Safety events, including serious adverse events and infections, were reported across arms.
This report summarizes Week 24 results presented at DDW 2026 from a randomized, double‑blind, placebo‑controlled phase 3 trial showing efficacy of an IL‑23 inhibitor for perianal fistulizing Crohn’s disease. The primary endpoint combined clinical closure and MRI confirmation of no significant collections.
The authors describe guselkumab as the first randomized trial to show efficacy of an IL‑23p19 antagonist in this specific manifestation. If you have perianal Crohn’s disease: these are trial results, not prescribing guidance.
Additional details (longer follow‑up, regulatory decisions, full published data) are needed before this would change clinical practice. For safety and individual treatment decisions, talk with your gastroenterologist.
Results are Week 24 data presented at a conference; full peer‑reviewed publication and longer‑term outcomes, safety details, and regulatory review are needed. The trial population had prior inadequate response to multiple therapies, which is relevant when considering generalizability.
